Click on each image below to explore the studies I’ve worked on.
The RADAR study is a UK-based Phase 2/3 clinical trial investigating risk-adapted and response-guided treatment strategies for newly diagnosed multiple myeloma patients eligible for stem cell transplantation. It examines how genetic risk factors and minimal residual disease (MRD) status can inform tailored treatment approaches, including the use of standard therapies and the novel immunotherapy isatuximab.
At the hospital, I contributed to this complex study primarily through meticulous data collection, helping to ensure the integrity of information critical to evaluating these personalised treatment strategies. Engaging with such an intricate trial deepened my appreciation for the role of precision medicine in oncology.
The UK Adult ITP Registry is a national research initiative collecting comprehensive clinical data on adults with primary immune thrombocytopenia (ITP), a rare autoimmune disorder characterized by low platelet counts and increased bleeding risk. By analysing patient information, the registry aims to enhance understanding of ITP's epidemiology, treatment responses, and long-term outcomes, including management during pregnancy .
At our hospital, I contributed to this study through meticulous data collection, ensuring the accuracy and completeness of patient records. Engaging with this registry has deepened my appreciation for the complexities of rare hematological conditions and the importance of robust data in informing clinical practice.
The CITRuS study is a feasibility trial exploring the use of electronic patient-reported outcome measures (ePROMs) to monitor and manage symptoms in colorectal cancer patients undergoing surgery or radiotherapy. By enabling patients to regularly report their symptoms online, the study aims to identify and address treatment-related side effects more promptly, improving patient care and quality of life.
I supported the study set-up at our site, reviewed protocol documents and amendments, and oversaw the study’s closure locally. It was a valuable experience in coordinating trial logistics and ensuring regulatory compliance in a digitally enhanced research setting.
BC-RECON is an observational study evaluating a novel DNA-based urine test (GALEAS™ Bladder) for the early detection of bladder cancer in patients attending haematuria clinics. By comparing the test against current standard investigations, the study aims to determine whether this non-invasive approach could accurately identify bladder cancer and reduce the need for unnecessary flexible cystoscopies, ultimately improving the patient experience while maintaining diagnostic accuracy.
I played a key role in recruiting participants, screening eligible patients, coordinating study appointments, collecting research samples and data, and conducting long-term follow-up with participants. Supporting this study gave me valuable experience in patient-centred research and highlighted the exciting potential of biomarker-based diagnostics to improve cancer detection while reducing the need for invasive procedures.
OSCAR is an observational study investigating whether advanced ‘omics’ technologies can identify biomarkers in urine and blood samples to improve the diagnosis of urological cancers, particularly prostate cancer. By analysing the genetic and molecular profiles associated with disease, the study aims to develop more accurate, non-invasive diagnostic tests that could reduce unnecessary invasive investigations and improve the early detection of urological cancers.
I supported this study through participant recruitment, contacting potential participants, collecting and processing biological samples, and ensuring accurate study documentation throughout each visit. Contributing to OSCAR provided valuable experience in biomarker research and reinforced the exciting potential of precision diagnostics to improve cancer detection while enhancing the patient experience.